Related by context. All words. (Click for frequent words.) 68 mocetinostat 67 PXD# 67 MGCD# [001] 66 MGCD# MGCD# [001] 66 INCB# [001] 66 HGS ETR1 66 PEG SN# 66 CYT# 65 mertansine 65 PSN# [002] 65 MGCD# MGCD# [002] 65 targeted kinase inhibitor 64 XL# XL# XL# 64 CUDC 64 sapacitabine 64 CCX# 64 OXi# 64 CA4P 64 mapatumumab 64 CRx 64 Phase Ib 64 Perifosine 64 oral prodrug 64 seliciclib 64 elotuzumab 64 AEG# 63 CoFactor 63 IMC A# 63 Cloretazine R VNP#M 63 talactoferrin 63 pralatrexate 63 TELINTRA 63 CR# vcMMAE 63 HDAC Inhibitor 63 PDX pralatrexate 63 perifosine 63 alvespimycin 62 MEK inhibitors 62 Triolex 62 orally administered inhibitor 62 XL# [003] 62 AzaSite Plus 62 PEG Interferon lambda 62 HDAC inhibitor 62 RGB # 62 VQD 62 celgosivir 62 ganetespib 62 HGS ETR2 62 Sym# 62 mocetinostat MGCD# 62 pomalidomide 62 valopicitabine 62 DAVANAT 62 SCH # 62 teduglutide 62 Chemophase 62 tanespimycin 62 Azixa 62 voreloxin 62 forodesine 62 novel anticancer 61 HspE7 61 anti leukemic 61 antitumor activity 61 AP# [003] 61 ISIS # 61 R#/MEM # 61 Archexin 61 thymalfasin 61 Tarceva TM 61 LEP ETU 61 ENMD # 61 XL# XL# 61 posaconazole 61 Targretin 61 lintuzumab 61 Carfilzomib 61 Traficet EN 61 Exelixis compounds 61 ALK inhibitor 61 Bortezomib 61 AQ4N 61 XL# XL# XL# XL# 61 RDEA# 61 Phase Ib II 61 Panzem R 61 GRN#L 61 PRT# 61 TKM ApoB 61 preclinical studies 61 INC# 61 CYC# 61 Proxinium TM 61 rNAPc2 61 FOLOTYN ® 60 Aurora kinase 60 nab paclitaxel 60 phase IIb clinical 60 FavId 60 docetaxel Taxotere R 60 Glufosfamide 60 sorafenib tablets 60 ARRY 60 erlotinib Tarceva ® 60 JAK1 60 tolerability profile 60 aflibercept 60 Panzem R NCD 60 MAP# 60 HCV protease inhibitor 60 EGFR HER2 60 PS# [001] 60 adecatumumab 60 decitabine 60 Zybrestat 60 tolerability 60 Phase Ib clinical 60 ZYBRESTAT 60 REOLYSIN ® 60 limiting toxicity 60 pan HDAC inhibitor 60 PNP inhibitor 60 AEZS 60 MEK inhibitor 60 PRTX 60 PLK1 SNALP 60 vidofludimus 60 Cloretazine 60 axitinib 60 IMGN# 60 investigational humanized monoclonal antibody 59 dacetuzumab 59 ongoing Phase 1b 59 CIMZIA TM 59 INCB# [002] 59 Imprime PGG 59 taxane 59 HGS# 59 BAY #-# 59 favorable pharmacokinetic profile 59 neratinib 59 Atiprimod 59 GSK # 59 enzastaurin 59 FOLFIRI 59 pertuzumab 59 Allovectin 7 ® 59 CEQ# 59 HCD# [002] 59 AVN# [001] 59 Cloretazine ® 59 PSMA ADC 59 Cintredekin Besudotox 59 Virulizin ® 59 kinase inhibitor 59 AAG geldanamycin analog 59 Nanobody 59 JAK inhibitors 59 BiTE antibody 59 obatoclax 59 #ME# 59 Androxal TM 59 Azedra TM 59 TELCYTA 59 CD# antibody [001] 59 MOZOBIL 59 OncoVEX GM CSF 59 NXL# 59 docetaxel 59 VEGF Trap 59 antiviral activity 59 trastuzumab Herceptin R 59 JAK inhibitor 59 veltuzumab 59 Fludara 59 vernakalant oral 59 Aurexis 59 investigational monoclonal antibody 59 Taxotere ® 59 Talactoferrin 59 ELACYT 59 carboplatin paclitaxel 59 dose limiting toxicities 59 TBC# 59 ThermoDox R 59 elagolix 59 IL# PE#QQR 59 dextromethorphan quinidine 59 Exelixis XL# 59 Bezielle 59 virus HCV protease inhibitor 59 TAFA# 59 Aplidin R 59 mGluR5 NAM 59 T DM1 59 DOS# 59 Amrubicin 59 ulimorelin 59 xenograft models 59 novel histone deacetylase 59 Alocrest 58 HER2 positive metastatic breast 58 phase Ib 58 milatuzumab 58 YONDELIS 58 HQK 58 HuLuc# 58 Marqibo 58 cMET 58 huC# DM4 58 ANA# 58 systemic RNAi therapeutic 58 FOLOTYN 58 tezampanel 58 Phase 1b clinical 58 Empatic 58 refractory multiple myeloma 58 palifosfamide 58 Elotuzumab 58 Apaziquone 58 phase IIa clinical 58 Azedra ™ 58 APD# 58 sunitinib malate 58 Solazed TM 58 multi kinase inhibitor 58 CORT # 58 sodium thiosulfate STS 58 Topical Interferon Alpha 2b 58 HuMax CD4 58 pegloticase 58 aflibercept VEGF Trap 58 orally bioavailable 58 Phase 1b 58 R roscovitine 58 EOquin 58 docetaxel Taxotere ® 58 Enzastaurin 58 MEK Inhibitor 58 Elagolix 58 AEGR 58 Panzem 58 PF # [001] 58 BRIM2 58 eniluracil 58 histone deacetylase HDAC inhibitor 58 glufosfamide 58 nitazoxanide 58 Hyphanox 58 pharmacodynamic properties 58 Taxotere R 58 tolerated dose MTD 58 Virulizin R 58 EFAPROXYN 58 OMP #M# 58 Vandetanib 58 Tezampanel 58 #D#C# 58 Phase Ib study 58 velafermin 58 XP# XP# 58 MDV# 58 Entereg R 58 MORAb 58 polymerase inhibitor 58 hA# 58 BZL# 58 budesonide foam 58 ARQ 58 dose cohorts 58 PEG PAL 58 PKC# 58 metaglidasen 58 PDE4 inhibitor 58 ascending dose 58 Fibrillex TM 58 mitomycin 58 sorafenib Nexavar 58 receptor tyrosine kinase inhibitor 58 dacarbazine 58 Azedra 58 selective androgen receptor modulator 58 AZD# 58 oral antiviral 58 TNFerade 58 XOMA 3AB 58 Dapagliflozin 58 TOCOSOL Paclitaxel 58 Alpharadin 58 CD# CEA 57 otelixizumab 57 EndoTAG TM -1 57 Symadex 57 mGluR5 negative 57 eltrombopag 57 fosbretabulin 57 eculizumab 57 Ozarelix 57 ADVEXIN 57 Anticalin R 57 secondary efficacy endpoints 57 low dose cytarabine 57 tipifarnib 57 pharmacokinetic interactions 57 telaprevir VX 57 Phase 2a trial 57 active comparator 57 CTA# Injection 57 tesmilifene 57 bavituximab 57 Asentar 57 evaluating tivozanib 57 Gemzar ® 57 delafloxacin 57 Phase IIa trials 57 GVAX ® 57 efficacy 57 non nucleoside HCV 57 Lenocta 57 protein kinase inhibitor 57 LE SN# 57 lesinurad 57 microtubule targeting 57 isavuconazole 57 IRX 2 57 Bicifadine 57 Pivotal Phase 57 AACR NCI EORTC 57 tyrosine kinase inhibitor 57 CBLC# 57 Triapine R 57 XL# anticancer compounds 57 preclinically 57 preclinical 57 Dasatinib 57 ALTU 57 MGd 57 Chrysalin 57 cell lymphoma CTCL 57 oral gallium 57 APTIVUS 57 APOPTONE 57 erlotinib 57 APF# 57 Valortim R 57 Icatibant 57 Phase 2a 57 pegylated liposomal doxorubicin 57 Phase 2b clinical 57 monotherapy 57 proteasome inhibitor 57 sunitinib Sutent ® 57 squalamine 57 NGX# 57 Phase 1b trial 57 dose escalation 57 Phase 2b trial 57 picoplatin 57 Personalized Immunotherapy 57 Locteron 57 Seliciclib 57 telomerase inhibitor drug 57 vivo efficacy 57 Onconase 57 metastatic HRPC 57 CIMZIA ™ 57 Vicinium TM 57 ixabepilone 57 Cloretazine R 57 relapsed refractory multiple myeloma 57 selective kinase inhibitor 57 hematological malignancies 57 torsemide ER 57 tumor xenograft models 57 FOLFOX6 chemotherapy regimen 57 polymerase inhibitors 57 immunomodulatory 57 randomized discontinuation trial 57 Tesetaxel 57 hypoxia activated prodrug 57 Xanafide 57 epothilone 57 orally dosed 57 LY# [003] 57 Amigal 57 CANCIDAS 57 oral proteasome inhibitor 57 unique alkylating agent 57 ApoB SNALP 57 novel VDA molecule 57 MAGE A3 ASCI 57 dose escalation trial 57 Civacir 57 NKTR 57 Phase Ib clinical trials 57 VNP#M 57 MAXY G# 57 ocular formulation 57 QLT# 57 liposomal formulation 57 IMP# 57 immunomodulator 57 Pivotal Phase III 57 adecatumumab MT# 57 NEUMUNE 57 belinostat 57 HRPC 57 Pharmos proprietary 57 BCX# 57 REOLYSIN 57 deforolimus 57 CD4 monoclonal antibody 57 delta isoform 57 OMP #R# 57 R sorafenib tablets 57 REOLYSIN R 57 DU #b 57 Budesonide MMX 57 telbivudine 57 Antiviral Activity 57 bevacizumab Avastin ® 57 bafetinib 57 Stedivaze 57 ofatumumab 57 cancer immunotherapies 57 CCR9 57 nonclinical studies 57 Exherin TM 57 Allovectin 7 R 57 velafermin belinostat 57 Phenoptin 57 Hsp# inhibitor 56 anticancer compound 56 6R BH4 56 Apoptone 56 ALN RSV# 56 DAVANAT R 56 ATL/TV# 56 Omacetaxine 56 NEUGENE 56 lintuzumab SGN 56 hematologic malignancies 56 galiximab 56 OPAXIO 56 anticancer activity 56 RITUXAN 56 INGN 56 ASONEP 56 PI3K/Akt pathway inhibitor 56 Anturol 56 Phase 2a clinical 56 carfilzomib 56 GLPG# 56 amrubicin 56 docetaxel chemotherapy 56 FOLPI 56 Protexia ® 56 Aflibercept 56 ISTODAX 56 dose escalation study 56 PREZISTA r 56 Azedra TM Onalta TM 56 cisplatin gemcitabine 56 S/GSK# 56 immunogenicity 56 MLN# 56 Inhalation Solution 56 bortezomib 56 tesetaxel 56 alfa 2a 56 Eltrombopag 56 nucleoside analog 56 Cethromycin 56 lenalidomide Revlimid R 56 CYT# potent vascular disrupting 56 cleavable linker 56 ARRY # 56 Pazopanib 56 GALNS 56 trastuzumab DM1 T DM1 56 Pralatrexate 56 EZN 56 satraplatin 56 ARIKACE 56 Palifosfamide 56 HCV polymerase inhibitor 56 estramustine 56 TRO# 56 phase IIb 56 TYGACIL 56 Trofex TM 56 pharmacodynamic profile 56 Golimumab 56 ara C 56 LymphoStat B 56 oral anticancer 56 torezolid phosphate 56 Celgosivir 56 cangrelor 56 μg dose 56 chemotherapy induced neutropenia 56 oral bioavailability 56 sorafenib 56 Fulvestrant 56 dosing regimens 56 Neulasta ® 56 investigational pan BCR 56 VAPRISOL 56 Phase 2a Clinical Trial 56 Protexia R 56 PREOS R 56 TRAIL receptor antibodies 56 DXL# 56 ataluren 56 TYKERB 56 visilizumab 56 evaluating Xcytrin 56 COPEGUS 56 EOquin TM 56 interferon gamma 1b 56 Dacogen injection 56 maximally tolerated dose 56 L Annamycin 56 OMNARIS Nasal Spray 56 carboplatin 56 metastatic castration resistant 56 oral ridaforolimus 56 brostallicin 56 Phase #b/#a 56 registrational 56 angiogenesis inhibitor 56 IAP inhibitors 56 Shigamabs ® 56 TKB# 56 Tolerability 56 dasatinib Sprycel ® 56 CD# monoclonal antibody 56 targeting CD# 56 Romidepsin 56 Immunotherapeutic 56 Tyrima 56 peripherally acting 56 cutaneous T cell 56 OvaRex R 56 Phase IIa trial 56 #mg/m# [001] 56 Vidofludimus 56 Epratuzumab 56 ceftazidime 56 Zemiva TM 56 custirsen 56 IMA# 56 ZADAXIN 56 DR Cysteamine 56 dacetuzumab SGN 56 docetaxel Taxotere 56 solithromycin 56 Voreloxin 56 SparVax TM 56 depsipeptide 56 Trastuzumab 56 ON #.Na 56 Genasense ® 56 sodium glucose cotransporter 56 Aplidin 56 Nexavar ® 56 nalbuphine ER 56 ALN TTR 56 PROMACTA 56 Neuradiab 56 Rebif ® 56 DOXIL 56 MET amplification 56 Blinatumomab 56 ERBITUX 56 MetMAb 56 CDK cyclin dependent 56 pharmacokinetics PK 56 retapamulin 56 LE DT 56 Phase Ia 56 Irinotecan 56 5 FU leucovorin 56 MAb 56 PCK# 56 urocortin 2 56 CB2 selective receptor agonist 56 refractory AML 56 DermaVir Patch 56 mRCC 56 Restanza 56 Hedgehog Pathway Inhibitor 56 potent antitumor activity 56 preclinical efficacy 56 Debio 56 temsirolimus 56 NOX E# 56 TORISEL 56 APTIVUS r 56 Tarvacin TM 56 elesclomol 56 teriflunomide 56 Trofex 56 GAP #B# 56 paclitaxel Taxol ® 56 cetuximab Erbitux ® 56 gemcitabine Gemzar 56 Phase III Pivotal 56 JAK3 56 Phase #b/#a clinical 55 5 fluorouracil 55 alpha folate receptor 55 Reolysin 55 HGS ETR1 mapatumumab 55 OMNARIS HFA 55 refractory gout 55 imetelstat 55 ALN PCS 55 ProLindac 55 ISENTRESS 55 BXT # 55 dependent kinase inhibitor 55 ACTEMRA 55 DexaSite 55 Actilon 55 nilotinib 55 tasimelteon 55 safety tolerability pharmacokinetic 55 pradefovir 55 Clolar ® 55 Aganocide R 55 SILENOR TM 55 ARIKACE ™ 55 CLORETAZINE TM VNP#M 55 RECOTHROM 55 targeted radiotherapeutic 55 LT NS# 55 thalidomide Thalomid 55 incyclinide 55 tramiprosate Alzhemed TM 55 sulodexide 55 Cetrorelix 55 IMiDs 55 investigational drug 55 evaluating satraplatin 55 MKC# PP 55 investigational compounds 55 oblimersen 55 NVA# 55 seliciclib CYC# 55 XmAb# 55 IgG1 monoclonal antibody 55 PEGPH# 55 investigational compound 55 plasma kallikrein inhibitor 55 Cotara 55 IFN α 55 uric acid lowering 55 GSK# [001] 55 Guanilib 55 MYCAMINE 55 ATL# [001] 55 Phase 2b study 55 iSONEP 55 Nexavar sorafenib 55 2 methoxyestradiol 55 investigational oral 55 romidepsin 55 Hsp# Inhibitor 55 TREANDA 55 tivozanib 55 CCR5 antagonist 55 Erlotinib 55 TG# [003] 55 Sapacitabine 55 severe hypersensitivity reactions 55 Dalbavancin 55 GFT# 55 tgAAC# 55 antiangiogenic activity 55 investigational immunotherapy 55 sapacitabine CYC# 55 MT# MEDI 55 Phase 2b 55 mg BID 55 Factor VIIa 55 IDX# 55 KRN# 55 c MET 55 comparator arm 55 UVIDEM 55 SinuNase 55 PTH analogue 55 HuMax EGFr 55 Panzem NCD 55 Satraplatin 55 Zerenex 55 Xcytrin 55 panitumumab Vectibix 55 Leukine 55 refractory chronic lymphocytic 55 AVE# 55 Monotherapy 55 non nucleoside 55 menadione 55 LibiGel ® 55 AKT inhibitor 55 Pegasys ® 55 huN# DM1 55 elacytarabine 55 cobiprostone 55 pharmacodynamic profiles 55 cannabinor 55 granisetron 55 mTOR inhibitors 55 PrevOnco ™ 55 Toxicities 55 Zolinza 55 vicriviroc 55 tubulin inhibitor 55 immunosuppressive compound 55 Randomized Phase 55 Akt inhibitor 55 Paraplatin ® 55 CINTREDEKIN BESUDOTOX 55 Ostarine 55 antitumor effects 55 ALN TTR# 55 viral kinetics 55 ALN VSP 55 alpha 2a 55 tamibarotene 55 L DOS# 55 Intravenous CP 55 bicifadine 55 Oral NKTR 55 indibulin 55 systemically administered 55 darinaparsin ZIO 55 albinterferon alfa 2b 55 COU AA 55 Myocet 55 Phase IIb clinical 55 TRIOLEX 55 vinorelbine 55 JVRS 55 oritavancin 55 Talabostat 55 SARMs 55 TLK# 55 Tamibarotene 55 Capesaris 55 REP# 55 TACI Ig 55 volociximab 55 pharmacokinetic properties 55 ONX 55 anti amnesic 55 pharmacokinetic PK 55 abiraterone acetate 55 ELOXATIN 55 atrasentan 55 SAR# [004] 55 urate lowering 55 JAK2 inhibitor 55 Aganocide 55 oral JAK1 55 melphalan prednisone 55 BrachySil 55 Valortim 55 Phase #/#a trial 55 riociguat 55 pharmacodynamic PD 55 vandetanib 55 Presents Preclinical Data 55 PROVENGE 55 ANYARA 55 Genasense ® oblimersen 55 HCV protease 55 humanized anti 55 CCX# B 55 GATTEX TM 55 cilengitide 55 afatinib 55 oncology indications 55 Valortim ® 55 Bevacizumab 55 TREDAPTIVE 55 alvimopan 55 PROSTVAC VF 55 Cleviprex TM clevidipine 55 phase IIb trial 55 vosaroxin 55 HSP# inhibitor 55 tolevamer 55 myelofibrosis polycythemia vera 55 Navelbine 55 potent antiviral 55 IAP inhibitor 55 PEG INTRON 55 pemetrexed 55 anti CD3 55 oral isoform selective HDAC 55 CCR9 antagonist 55 telaprevir dosing 55 placebo controlled Phase 55 CTAP# Capsules 55 solid tumors 55 BNC# 55 Pimavanserin 55 Phase III clinical 55 FOLFOX 55 generation proteasome inhibitor 55 sorafenib Nexavar ® 55 metastatic hormone refractory 55 oral picoplatin 55 Lenocta TM 55 PI3K/mTOR 54 Anidulafungin 54 pharmacokinetic profile 54 mitogen activated ERK kinase 54 ELND# 54 UPLYSO 54 investigational protease inhibitor 54 Octreolin 54 dexpramipexole 54 LEUKINE 54 Calcitonin 54 orally administered 54 Afatinib 54 Trofex ™ 54 ZK EPO 54 elvitegravir 54 EVIZON TM squalamine lactate 54 blinatumomab 54 metastatic renal cell carcinoma 54 Genasense 54 INT# [002] 54 Sulonex TM 54 platinum refractory 54 myopathy rhabdomyolysis 54 PEGylated interferon beta 1a 54 Copegus ribavirin 54 NS4A 54 Zenvia ™ 54 ozarelix 54 talabostat 54 humanized monoclonal antibody 54 pharmacodynamic markers 54 erythropoietic 54 RSD# oral 54 composite endpoint 54 TYZEKA 54 Alzhemed TM 54 AzaSite Xtra 54 antiangiogenic 54 imatinib Gleevec ® 54 SNALP technology 54 TG# [001] 54 Epothilone D 54 pharmacokinetics 54 Pemetrexed 54 initiate Phase 1b 54 GVAX R 54 lorvotuzumab mertansine 54 anti angiogenic agent 54 DDP# 54 NexACT 54 PEGylated 54 histone deacetylase inhibitor 54 BAL# [001] 54 candidate AQ4N 54 ispinesib 54 Mipomersen 54 standard chemotherapy regimen 54 dose cohort 54 ularitide 54 Nexavar 54 Homspera 54 intravesical infusion therapy 54 ZOLINZA 54 Nasulin 54 p# biomarker 54 multicenter Phase III 54 Randomized Double blind 54 angiotensin receptor blocker ARB 54 Phase IIb 54 VEGF receptor inhibitor 54 nucleoside 54 SPRYCEL ® 54 GRNVAC1 54 LY# [002] 54 Zemiva TM Trofex TM 54 CD3 monoclonal antibody 54 Pharmacokinetic PK 54 isatoribine 54 daclizumab 54 Vitaxin 54 HEPLISAV 54 Synavive 54 Phase III 54 gemcitabine 54 ancrod 54 HDAC 54 SERMs 54 ThermoDox ® 54 Tarvacin 54 ORMD 54 TOLAMBA 54 PrevOnco 54 ORENCIA R 54 perifosine KRX 54 HuMax CD# 54 methylnaltrexone 54 PI3K inhibitor 54 C1 INH 54 combinability 54 molecularly targeted 54 telomerase therapeutic 54 CK # 54 DLTs 54 non nucleoside inhibitor 54 small molecule chemotherapeutic 54 Belinostat 54 PREOS 54 tezampanel NGX# 54 OHR/AVR# 54 vinca alkaloid 54 idarubicin 54 RNAi therapeutic targeting 54 Defibrotide 54 Aganocide ® 54 BRAF inhibitor 54 PRX # 54 Phase IIa clinical 54 selective immunoproteasome inhibitor 54 efficacy tolerability 54 Paclitaxel 54 rFIXFc 54 Viramidine 54 Zoraxel 54 Milatuzumab 54 IMC #B 54 BiTE 54 tipranavir 54 Squalamine 54 azacitidine 54 iniparib 54 TRISENOX ® 54 darapladib 54 sunitinib 54 S1P antibody 54 KNS # 54 Panitumumab 54 FTY# 54 gefitinib 54 entinostat 54 Cutaneous T 54 daptomycin 54 oxidative stress inducer 54 daunorubicin 54 immunomodulating 54 tolvaptan 54 subcutaneous formulation 54 Darusentan 54 calcitonin 54 Leukine ® 54 candidate CRLX# 54 reslizumab 54 Gemcitabine 54 Xeloda ® 54 immunomodulatory therapy 54 cyclophilin inhibitor 54 metastatic castrate resistant 54 pegylated interferon alfa 2b 54 highly selective inhibitor 54 active moiety 54 bortezomib Velcade 54 rituximab 54 ruxolitinib 54 Tovaxin 54 Nanobody ® 54 LibiGel Phase III 54 THR beta agonist 54 efficacy endpoints 54 Curaxin CBLC# 54 registrational studies 54 PREZISTA rtv 54 palifosfamide Zymafos TM 54 RG# [001] 54 GLP toxicology studies 54 SILENOR 54 interferon alfa 54 HCV polymerase 54 apremilast 54 Preclinical studies 54 CRMD# 54 LHRH antagonists